The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)

NCT07160647 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

dMMR/MSI-H-type Rectal Adenocarcinoma

Interventions

DRUG: Ipalolimab and Tovorilimab

Sponsor

Sir Run Run Shaw Hospital